W
WIMI Biotech
Crop gene editing and high-throughput plant transformation platform
About WIMI Biotech
Wimi Biotechnology Co., Ltd. is a Chinese company founded in 2017 that focuses on precision breeding and biotechnology applications for major crops. The company, led by Chairman and CEO Dr. Jieting Xu, provides fee-for-service plant transformation and gene-editing services to agricultural research institutions and enterprises.
Wimi Bio has developed a high-throughput, genotype-independent genetic transformation platform for over 20 crops, including maize, rice, soybeans, and wheat. Its core technologies include an independently developed CAS12 enzyme, a universal genetic manipulation system, and high-volume gene editing capabilities. The company aims to improve crop traits such as insect and herbicide resistance, yield, and nutritional value. For instance, they have developed gene-edited maize with traits like high planting resistance and increased vitamin E. Beyond trait improvement, Wimi Bio is also using synthetic biology to develop functional products like dietary nutrients and oral edible vaccines.
The company serves over 1,000 institutions globally and utilizes a Laboratory Information Management System (LIMS) to ensure transparency and data integrity throughout the experimental process. In September 2024, Wimi Bio secured a Series A funding round of $14.1 million from investors including Changzhou Hi-tech Group and Sanya Yazhouwan Technology City Holding Group. The company has been recognized for its work, being named one of "China's 65 Most Socially Influential Startups in 2023" by Fortune China for its contributions to the seed industry and food security.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Qingdao, China
- Open positions
- None listed
- Dealroom signal
- 14.3/100
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2024 | $14M | $55M | Yazhou Bay Venture Capital · Changjin Holdings · Jiaxing Deshi Private Equity Fund Management | ↗ |
| SEED✓Equity / VC | Apr 2023 | $2.8M | $11M | HosenCare Brothers | ↗ |
Growth signals
Latest recorded traffic for WIMI Biotech is 230 monthly website visits, up 360% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- HBHosenCare Brothers
Series A3 investors entered at this stage
- YCYazhou Bay Venture Capital
- CHChangjin Holdings
- JMJiaxing Deshi Private Equity Fund Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about WIMI Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See WIMI Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.